Replies to post #484570 on Anavex Life Sciences Corp (AVXL)

[falconer66a]

Medicare Costs and Blarcamesine

And the cheapest solution potentially available, blacarsamine, [to treat Alzheimer's] will benefit if there was belt-tightening.

As we know, increasing numbers of the elderly are succumbing to Alzheimer's disease each year. They all will need treatment; which in the U.S will involve Medicare or other government funding sources.

The existing Alzheimer's treatments, the FDA-approved monoclonal antibody drugs, Leqembi, etc., are extremely expensive. Blarcamesine won't be. The cost difference will be a powerful driver for blarcamesine approval and utilization; across the Western world. Government medical insurance agencies save lots and lots of money. Patients do, too. And, blarcamesine is far easier and convenient to take, a single pill a day. No need to be taken to a radiology center to get periodic brain scans to check for brain hemorrhaging or shrinkage. Most importantly, blarcamesine will exhibit far better treatment outcomes.

Blarcamesine, and Anavex (and its shareholders) will win.